pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ultragenyx Pharmaceutical Inc. ($RARE) · news · pharmadog
← back to Ultragenyx Pharmaceutical Inc.
News mentioning $RARE
837
stories
Jun 2, 26
Travere pays Everest $112M upfront to grow rare kidney disease pipeline
endpoints
Jun 2, 26
STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
stat
Jun 2, 26
FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
fda press
Jun 2, 26
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
biopharma dive
Jun 2, 26
How one state’s medical meal program lowered health care costs
stat
Jun 1, 26
STAT+: Global coalition to fast-track three vaccines targeting Ebola outbreak with $62 million in funding
stat
Jun 1, 26
STAT+: At the world’s largest cancer research meeting, data briefly took a backseat to grief
stat
Jun 1, 26
RallyBio tries again for reverse merger, this time with Avenzo
biopharma dive
Jun 1, 26
#ASCO26: Lilly's plenaries; Incyte's frontline data in lymphoma
endpoints
Jun 1, 26
Servier buys into muscular dystrophy with potentially $2.7B deal
biopharma dive
Jun 1, 26
Opinion: What should hospitals do when patients demand unvaccinated donor blood?
stat
Jun 1, 26
STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
stat
Jun 1, 26
2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?
biopharma dive
Jun 1, 26
STAT+: Executives reveal tech initiatives at Summa Health, eight months after General Catalyst acquisition
stat
May 31, 26
STAT+: A standing ovation for RevMed, and caution for Akeso
stat
May 30, 26
STAT+: China competition, ‘destruction’ at FDA give agency chance to restructure, Rick Pazdur says
stat
May 29, 26
Kenya court suspends U.S. plan for Ebola quarantine facility for Americans
stat
May 29, 26
Agios ends development of tebapivat in low-risk MDS following subpar results
endpoints
May 29, 26
Allogene CEO to step down; Agios drug fails key test
biopharma dive
May 28, 26
AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
endpoints
May 19, 26
How AI helped treat a newborn’s ultra rare disease. ‘It was almost like a light switch.’
stat
May 19, 26
BioMarin drug acquired in buyout misses goal in rare disease study
biopharma dive
May 19, 26
STAT+: A new ranking of pharma companies by R&D performance
stat
May 19, 26
Relay drug shows early promise against rare blood vessel diseases
biopharma dive
May 19, 26
Relay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
endpoints
May 19, 26
BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test
endpoints
May 18, 26
Amgen stands by rare disease drug Tavneos amid Japan liver toxicity report
endpoints
May 18, 26
Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
biopharma dive
May 18, 26
Texas is opening up a detransition clinic
stat
May 18, 26
Opinion: ‘Patient autonomy’ has nothing to do with childhood vaccine policies
stat
← prev
page 24 of 28
next →
